Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab
Authors:
Open Access
- 1 October 2009
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 114 (14) , 3052-3055
Abstract
Neutropenia is a recognized adverse event in patients treated with the humanized anti-CD52 monoclonal antibody alemtuzumab. However, as it is widely believed that neutrophils do not express CD52, the etiology of alemtuzumab-associated neutropenia is unclear. We have found that neutrophils express both mRNA coding for CD52 and the protein itself on the cell surface. We confirmed cell-surface expression using 3 different anti-CD52 antibodies, and note that neutrophils express lower levels of CD52 than lymphocytes and eosinophils. Further, incubation of alemtuzumab with neutrophils results in dose-dependent, complement-mediated lysis in the presence of both heterologous and autologous complement. These data offer an explanation for the etiology of alemtuzumab-associated neutropenia. In a climate of increased use of alemtuzumab in leukemia and other disease states, as well as in transplantation, these data highlight the need for increased vigilance of emerging neutropenia in patients treated with alemtuzumab.Keywords
This publication has 20 references indexed in Scilit:
- Alemtuzumab Therapy for Hypereosinophilic Syndrome and Chronic Eosinophilic LeukemiaClinical Cancer Research, 2008
- FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic LeukemiaThe Oncologist, 2008
- Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2007
- Role of antibody therapy in lymphoid malignanciesBritish Medical Bulletin, 2007
- Alemtuzumab Induction and Tacrolimus Monotherapy in Pancreas Transplantation: One- and Two-Year OutcomesTransplantation, 2006
- Living Donor Renal Transplantation Using Alemtuzumab Induction and Tacrolimus MonotherapyAmerican Journal of Transplantation, 2006
- Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemiaLeukemia, 2005
- Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)Leukemia, 2004
- Long-term remission of intractable systemic vasculitis with monoclonal antibody therapyThe Lancet, 1993
- Reshaping human antibodies for therapyNature, 1988